Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA readies for cough/cold meeting

This article was originally published in The Tan Sheet

Executive Summary

An FDA spokeswoman said Sept. 26 the agenda for the Oct. 2 meeting on OTC cough/cold products has yet to be finalized but approximately 28 parties are scheduled to make presentations. Since announcing the meeting Aug. 25, FDA has received comments from two parties, including Wayne Snodgrass, one of the petitioners whose filing led to FDA's review of pediatric cough/cold safety (1"The Tan Sheet" Oct. 22, 2007, p. 3)

You may also be interested in...

FDA Panel Narrowly Votes Against Cough/Cold Drugs For Children Up To Age 6

An FDA advisory panel decided in split votes Oct. 19 to recommend immediately that all OTC cough/cold medicines should not be used for 2-to 5-year-old children but are safe for 6- to 12-year-olds

Coronavirus: Can Companies Achieve Vaccine Ambition?

Brilinta Boost For AZ In Stroke Study





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts